John de Groot

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla et al. · Nature Medicine · 2019 · 1.3K citations

Neuro-oncology, Neoadjuvant Anti-pd-1 Immunotherapy, Tumor Immunology +14

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

Nicholas Butowski, Howard Colman, John de Groot et al. · Neuro-Oncology · 2015 · 562 citations · Full text

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

John de Groot, Gregory N. Fuller, Ashok J. Kumar et al. · Neuro-Oncology · 2010 · 499 citations · Full text

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

Funda Meric‐Bernstam, Lauren Brusco, Kenna Shaw et al. · Journal of Clinical Oncology · 2015 · 424 citations · Full text

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

Tiffany R. Hodges, Martina Ott, Joanne Xiu et al. · Neuro-Oncology · 2017 · 419 citations · Full text